Top Markets
#1 Velas Velas +480.91%
#2 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#3 Siren Siren +107.10%
#4 Venom Venom +47.47%
#5 Gigachad Gigachad +25.21%
#6 Ontology Ontology +20.20%
#7 Scor Scor +17.10%
#8 TRIA TRIA +16.34%
#9 Dacxi Dacxi +16.27%
#10 BabyBoomToken BabyBoomToken +13.98%
Coin of the day
Velas Velas
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Classifica tra le azioni #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Prezzo delle azioni
$0.0416118
Capitalizzazione di mercato
$12.78M
Variazione (1 giorno)
1.72%
Variazione (1 anno)
-22.01%
Paese
AU
Scambia Noxopharm Limited (NOX)

Categoria

Healthcare
EPS per Noxopharm Limited (NOX)
EPS al December 2025 TTM: $-0.01
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Noxopharm Limited, l’EPS attuale della società (TTM) è $-0.01. Alla fine del 2024, la società aveva un EPS di $-0.01 una diminuzione rispetto a rispetto a quello del 2023, che era di $-0.03.
Storico EPS per Noxopharm Limited da 2016 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
2026 (TTM) $-0.01 25.00%
2025 $-0.01 35.80%
2024 $-0.01 -76.38%
2023 $-0.03 -22.40%
2022 $-0.04 66.79%
2021 $-0.03 1,792.86%
2020 0.00 -97.54%
2019 $-0.06 -48.69%
2018 $-0.11 314.55%
2017 $-0.03 66.46%
2016 $-0.02 0.00%
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $3.62 -29,078.40%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $15.47 -123,860.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $43.12 -345,060.00%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.62 -77,066.40%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $2.98 -23,940.00%
AU